GCM
REGN icon

Gator Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Gator Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,000
Closed -$2.32M – 90
2026
Q1 		$2.32M Sell
3,000
-282
-9% -$216K 0.47% 53
2025
Q4 		$2.53M Buy
+3,282
New +$2.23M 0.51% 53

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Gator Capital Management's REGN Position: Q2 2026 in Review

Gator Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 3,000 shares — an estimated $2.32M sold.

Gator Capital Management first reported a position in REGN in Q4 2025 and held it in 2 quarters. The position peaked at $2.53M in Q4 2025. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Gator Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Gator Capital Management sold 3,000 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $2.32M.
  • Gator Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Gator Capital Management's Regeneron Pharmaceuticals position peaked at $2.53M in Q4 2025.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Gator Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.